Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has shared an announcement.
AstraZeneca has secured U.S. FDA approval for Breztri Aerosphere as the first and only single-inhaler triple-combination maintenance therapy for asthma in patients aged 12 and older, expanding its use beyond chronic obstructive pulmonary disease. The decision was backed by Phase III KALOS and LOGOS data showing statistically significant and clinically meaningful lung-function improvements versus standard dual ICS/LABA therapy, with rapid onset and no new safety concerns.
The approval opens up a substantial new market among the 27 million Americans living with asthma, roughly half of whom remain uncontrolled on dual therapies and face ongoing exacerbation risk. Breztri, already the fastest-growing fixed-dose triple therapy in COPD and approved for that indication in 90 countries, strengthens AstraZeneca’s respiratory franchise and underpins ongoing regulatory filings for asthma in major markets including the EU, Japan and China.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing and commercialising prescription medicines across Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, it has a 50-year heritage in respiratory care and markets innovative therapies in more than 125 countries, positioning Respiratory & Immunology as a key growth driver.
Average Trading Volume: 2,665,397
Technical Sentiment Signal: Buy
Current Market Cap: £216.4B
Learn more about AZN stock on TipRanks’ Stock Analysis page.